These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 31501414)

  • 1. A positive feedback loop of β-catenin/CCR2 axis promotes regorafenib resistance in colorectal cancer.
    Ou B; Cheng X; Xu Z; Chen C; Shen X; Zhao J; Lu A
    Cell Death Dis; 2019 Sep; 10(9):643. PubMed ID: 31501414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer.
    Liu YC; Tsai JJ; Weng YS; Hsu FT
    Biomed Pharmacother; 2020 Aug; 128():110319. PubMed ID: 32502841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer.
    Fan LC; Teng HW; Shiau CW; Tai WT; Hung MH; Yang SH; Jiang JK; Chen KF
    Oncotarget; 2016 Sep; 7(39):64136-64147. PubMed ID: 27580057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer.
    Schmieder R; Hoffmann J; Becker M; Bhargava A; Müller T; Kahmann N; Ellinghaus P; Adams R; Rosenthal A; Thierauch KH; Scholz A; Wilhelm SM; Zopf D
    Int J Cancer; 2014 Sep; 135(6):1487-96. PubMed ID: 24347491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive feedback loop of hepatoma-derived growth factor and β-catenin promotes carcinogenesis of colorectal cancer.
    Lian J; Tang J; Shi H; Li H; Zhen T; Xie W; Zhang F; Yang Y; Han A
    Oncotarget; 2015 Oct; 6(30):29357-74. PubMed ID: 26296979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer.
    Zhang WJ; Li Y; Wei MN; Chen Y; Qiu JG; Jiang QW; Yang Y; Zheng DW; Qin WM; Huang JR; Wang K; Zhang WJ; Wang YJ; Yang DH; Chen ZS; Shi Z
    Cancer Lett; 2017 Feb; 386():100-109. PubMed ID: 27864115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SHP-1 is a target of regorafenib in colorectal cancer.
    Fan LC; Teng HW; Shiau CW; Lin H; Hung MH; Chen YL; Huang JW; Tai WT; Yu HC; Chen KF
    Oncotarget; 2014 Aug; 5(15):6243-51. PubMed ID: 25071018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.
    Napolitano S; Martini G; Rinaldi B; Martinelli E; Donniacuo M; Berrino L; Vitagliano D; Morgillo F; Barra G; De Palma R; Merolla F; Ciardiello F; Troiani T
    Clin Cancer Res; 2015 Jul; 21(13):2975-83. PubMed ID: 25838391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study.
    Wang YJ; Zhang YK; Zhang GN; Al Rihani SB; Wei MN; Gupta P; Zhang XY; Shukla S; Ambudkar SV; Kaddoumi A; Shi Z; Chen ZS
    Cancer Lett; 2017 Jun; 396():145-154. PubMed ID: 28302530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer.
    Song X; Shen L; Tong J; Kuang C; Zeng S; Schoen RE; Yu J; Pei H; Zhang L
    Theranostics; 2020; 10(18):8098-8110. PubMed ID: 32724460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRIB3 Interacts With β-Catenin and TCF4 to Increase Stem Cell Features of Colorectal Cancer Stem Cells and Tumorigenesis.
    Hua F; Shang S; Yang YW; Zhang HZ; Xu TL; Yu JJ; Zhou DD; Cui B; Li K; Lv XX; Zhang XW; Liu SS; Yu JM; Wang F; Zhang C; Huang B; Hu ZW
    Gastroenterology; 2019 Feb; 156(3):708-721.e15. PubMed ID: 30365932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological Targeting SHP-1-STAT3 Signaling Is a Promising Therapeutic Approach for the Treatment of Colorectal Cancer.
    Fan LC; Teng HW; Shiau CW; Tai WT; Hung MH; Yang SH; Jiang JK; Chen KF
    Neoplasia; 2015 Sep; 17(9):687-696. PubMed ID: 26476076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis.
    Chen D; Wei L; Yu J; Zhang L
    Clin Cancer Res; 2014 Jul; 20(13):3472-84. PubMed ID: 24763611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gankyrin sustains PI3K/GSK-3β/β-catenin signal activation and promotes colorectal cancer aggressiveness and progression.
    He F; Chen H; Yang P; Wu Q; Zhang T; Wang C; Wei J; Chen Z; Hu H; Li W; Cao J
    Oncotarget; 2016 Dec; 7(49):81156-81171. PubMed ID: 27835604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regorafenib suppresses colon tumorigenesis and the generation of drug resistant cancer stem-like cells via modulation of miR-34a associated signaling.
    Cai MH; Xu XG; Yan SL; Sun Z; Ying Y; Wang BK; Tu YX
    J Exp Clin Cancer Res; 2018 Jul; 37(1):151. PubMed ID: 30005681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of MCP-1 in alcohol-induced aggressiveness of colorectal cancer cells.
    Xu M; Wang S; Qi Y; Chen L; Frank JA; Yang XH; Zhang Z; Shi X; Luo J
    Mol Carcinog; 2016 May; 55(5):1002-11. PubMed ID: 26014148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation.
    Tong J; Tan S; Zou F; Yu J; Zhang L
    Oncogene; 2017 Feb; 36(6):787-796. PubMed ID: 27399335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel ent-kaurane diterpenoid executes antitumor function in colorectal cancer cells by inhibiting Wnt/β-catenin signaling.
    Ye Q; Yao G; Zhang M; Guo G; Hu Y; Jiang J; Cheng L; Shi J; Li H; Zhang Y; Liu H
    Carcinogenesis; 2015 Mar; 36(3):318-26. PubMed ID: 25600769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRIM21 induces selective autophagic degradation of c-Myc and sensitizes regorafenib therapy in colorectal cancer.
    Ye WL; Huang L; Yang XQ; Wan S; Gan WJ; Yang Y; He XS; Liu F; Guo X; Liu YX; Hu G; Li XM; Shi WY; He K; Wu YY; Wu WX; Lu JH; Song Y; Qu CJ; Wu H
    Proc Natl Acad Sci U S A; 2024 Oct; 121(42):e2406936121. PubMed ID: 39388269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of dopamine receptor D2 promotes colorectal cancer progression by activating the β-catenin/ZEB1 axis.
    Lee H; Shim S; Kong JS; Kim MJ; Park S; Lee SS; Kim A
    Cancer Sci; 2021 Sep; 112(9):3732-3743. PubMed ID: 34118099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.